Heterogeneous SSTR2 target expression and a novel

In this case report, we present the treatment outcomes of the first patient enrolled in the LuDO-N trial. The patient is a 21-month-old girl diagnosed with high-risk neuroblastoma (NB) and widespread skeletal metastasis. The patient initially underwent first-line therapy according to SIOPEN HRNBL-1 but was switched to second-line treatments due to disease progression, and she was finally screened for enrollment in the LuDO-N trial due to refractory disease. Upon enrollment, the patient received two rounds of the radiolabeled somatostatin analogue lutetium-177 octreotate (

Informations de copyright

Copyright © 2024 Park, Fransson, Sundquist, Nilsson, Grybäck, Wessman, Strömgren, Djos, Fagman, Sjögren, Georgantzi, Herold, Kogner, Granberg, Gaze, Martinsson, Karlsson and Stenman.

Déclaration de conflit d'intérêts

JJES is affiliated with the companies Expression Analytics Oy and Trifma Oy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare that this study received funding from the Swedish Childhood Cancer Fund, Swedish Cancer Society, Region Stockholm, and Advanced Accelerator Applications/Novartis (AAA). AAA had the following involvement in the study: financial support of the trial, provision of the investigational medicinal product (IMP) as well as non-IMPs free of charge.